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Abstract
Hyperhomocysteinemia is known to be associated
with an increased risk of myocardial infarction, stroke,
peripheral arterial disease, and venous thrombosis.
Gene polymorphisms in methylenetetrahydrofolate
reductase (MTHFR) and methionine synthase (MS)
may account for reduced enzyme activity and hyper-
homocysteinemia. A recent study has documented
evidence of polygenic regulation of plasma homo-
cyteine. We report here on a case of occlusive stroke
at young age and hyperhomocysteinemia with ho-
mozygous V/V (677C to T) variant in the MTHFR
gene as well as homozygous D/D (2756G to A) vari-
ant in the MS gene.
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Introduction
Hyperhomocysteinemia is known to be associated with
risk or severity of cardiovascular diseases and cerebro-
vascular diseases (Wilcken and Wilcken, 1976; Stampfer
et al., 1992; Boushey et al., 1995; Perry et al., 1995).
Biochemically, homocysteine is a naturally occurring
sulfhydryl amino acid and its metabolism is regulated by
two major pathways, re-methylation to methionine and
trans-sulfuration to cysteine (Harmon et al., 1996). The
conversion of homocysteine to methionine occurs through
re-methylation step with N5-methyl-tetrahydrofolate, which
is formed from N5,N10-methylene-tetrahydrofolate in a
reaction catalyzed by methylene tetrahydrofolate reduc-
tase (MTHFR) (Makris, 2000). In addition, methionine
synthase (MS) catalyzes the re-methylation of homocy-
steine to methionine in a methyl-cobalamine dependent
reaction (Harmon et al., 1999). In the trans-sulphuration
pathway, homocysteine condenses with serine to form
cystathionine in a reaction catalyzed by cystathionine β-
synthase (CBS) (Sacco et al., 1998).
In 1988, Kang et al. described a thermolabile variant
of MTHFR that is associated with decreased enzyme
activity and mildly elevated plasma homocysteine levels.
The responsible mutation in the MTHFR gene, a C →
T substitution at the base pair 677 leading to the ex-
change of an alanine to a valine, was identified by
Frosst et al. in 1995.
In 1996, Leclerc et al. identified a missense mutation
of MS gene, D919G, which is common in the general
population and inferred that it might lead to mild hy-
perhomocysteinemia with a consequent effect on vascular
disease.
In the present study, we describe a case of hyperho-
mocysteinemia with stroke at young age with identification
of homozygous V/V (677C to T) and D/D (2756G to A)
variants in the MTHFR and MS genes, respectively.
Materials and Methods
Case
A 21 years old man (non-smoker) suffered from recurrent
paresthesia and weakness of left arm and leg for
several days. There was neither previous nor family
history of thrombosis or hypertension. Brain MRI study
revealed an infarct on the right basal ganglia and caudate
nucleus area. Extensive search for an underlying pre-
disposition to thrombosis was done in parallel with
routine complete blood count and biochemical tests. All
the results including serum cholesterol level were normal
except for elevated Lp(a) (57 mg/dl; normal reference
range, < 30 mg/dl) and total homocysteine (22.2 nM/ml;
normal reference range, 6-15 nM/ml) levels. Pre-ther-
apeutic serum vitamin B12 level was also normal (240
pg/ml; normal reference range, 190-914 pg/ml) and
folate level was 2.7 ng/ml, which was slightly decreased,
compared with normal reference range (> 3.0 ng/ml).
DNA study was undertaken to observe the genotypes of
CBS, MTHFR and MS genes. The patients’ parents and
one sister were also included for the genetic DNA study.
Oral anticoagulant therapy was performed.
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Homocysteine assay
Homocysteine was measured 3 months after the stroke
as total homocysteine (i.e., free and protein-bound forms)
in fasting plasma collected in an ethylenediaminetetra-
acetic acid (EDTA) tube. Homocysteine was reduced by
tri-n-butylphosphine and was determined by means of
high-performance liquid chromatographic analysis as
previously described (Araki and Sakoy, 1987).
DNA study
Genomic DNA was extracted from peripheral blood
samples drawn into EDTA tubes using a commercially
available DNA isolation kit (Easy-DNA, Invitrogen, USA).
Polymerase chain reaction (PCR) amplification of geno-
mic DNA was performed using specific oligonucleotide
primers for MS D/G genotype, MTHFR A/V genotype,
and CBS 844ins68 genotype as previously described
(Morita et al., 1998; Morita et al., 1999; Tsai et al., 2000).
We used digestion with HaeIII and HinfI restriction enzy-
mes for the detection of A2756G variant of the MS gene
and C677T variant of the MTHFR genes, respectively.
Results
As shown in Figures 1 and 2, the proband was found to
have V/V genotype (A222V) in the MTHFR gene
polymorphism (C677T) and D/D genotype (D919G) in
the MS gene polymorphism (A2756G). However, as
shown in the Figure 2, the proband was not a carrier of
844ins68 allele of CBS gene. Genotypes of the proband
as well as his family members were summarized in
Table 1.
Discussion
Strokes remain as the leading cause of death in Korean
population with high mortality (80/100000), in which
cerebral infarction is predominantly involved (Yoo et al.,
1998). The conventional risk factors for cerebral infarction
in Koreans include hypertension, smoking, hyperchole-
sterolemia, diabetes, and aging (The Korean Neurological
Association, 1993). Routine laboratory tests to detect
hereditary or acquired thrombotic disorders are not war-
ranted in older patients with stroke due to the presence
of atherosclerosis of the carotid or cerebral arteries.
However, in younger adults in whom there is no obvious
reason for stroke, a search for an underlying predispo-
Figure 1. Restriction enzyme analysis of MS and MTHFR genes in the
proband and his family. The A2756G (D919G) substitution of MS gene
creates a HaeIII recognition sequence which digests the 189 bp fragment
into 159 and 30 bp fragments (Lane 1: proband, D/D; Lane 2: father, D/G;
Lane 3: mother, D/D; Lane 4: sister, D/D). The C677T (A222V) substitution
of MTHFR gene creates a HinfI recognition sequence which digests the 198
bp fragment into 177 and 21 bp fragments (Lane 7: proband, V/V; Lane 8:
father, V/A; Lane 9: mother, V/A; Lane 10: sister, V/A). Lane 5 and 6: intact
PCR products of proband before digestion. Lane M: DNA size marker, 100
bp ladder.
Figure 2. Polymerse chain reactions of CBS gene in the proband and his
family. The 68 bp insertion (844 ins68) of CBS gene creates 252 bp instead
of 184 bp without 68 bp insertion (Lane 1: proband; Lane 2: father; Lane 3:
mother; Lane 4: sister). All the products showed no insertions. Lane M: DNA
size marker, 100 bp ladder.






Proband V/V D/D Ins68 −/−
Father V/A D/G Ins68 −/−
Mother V/A D/D Ins68 −/−
Sister V/A D/D Ins68 −/−
MTHFR, methylene tetrahydrofolate reductase; MS, methionine synthase;
CBS, cystathionine β-synthase.
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sition to thrombosis can be fruitful and could alter
therapy (Hathaway and Goodnight, 1993). As a result of
clinical investigation to search any other risk factors in
addition to dyslipidemia, we present a patient with an
elevated plasma homocysteine level and variations in the
MTHFR and MS genes, which code for key enzymes in
the homocysteine metabolic pathways.
The association between homocysteinemia and stroke
have been reported in previous studies (Brattstrom et
al., 1990; Coull et al., 1990; Verhoef et al., 1994), and
multivariate adjusted odds ratio for the highest quartile
versus the lowest was 2.5 among whites (Giles et al.,
1998). This association may not differ by race and the
odds ratio of the highest 5% of homocysteine levels in
control group in Koreans was reported to be 1.70 after
an adjustment for known risk factors (Yoo et al., 1998).
A common missense mutation, A222V, has been
identified in the MTHFR gene, where substitution of
alanine (A) by valine (V) results in a thermolabile variant
with 50% reduced enzymatic activity at 37oC and
complete loss of activity at 46oC (Kang et al., 1988;
Frosst et al., 1995). This thermolabile variant has been
consistently associated with mild elevations of plasma
homocystein concentration (Brattstrom et al., 1998). In
fact, individuals homozygous for the V222 allele were
reported to have 1.6 nM/ml higher homocysteine com-
pared to individuals with the other genotypes, and the
effect of the thermolabile variant was particularly pro-
found in the presence of low folate levels (Dekou et al.,
2001). A significant decrease of blood folate concen-
trations in a subgroup of stroke patients who had in-
creased plasma homocysteine concentrations has also
been described (Hultberg et al., 1997). Thus the increase
in plasma homocysteine concentration in the present
case may partly be caused by a marginal folate defi-
ciency. Therefore, folate supplement could have a ther-
apeutic importance to abolish the V/V genotype effect in
the present case.
Leclerc et al. (1996) described the D919 polymorphism
in the MS gene and the results from the study of healthy
men have demonstrated that the D919G polymorphism
has a modest effect on homcysteine levels, with carriers
of the G919 allele having levels 0.6 nM/ml lower than
homozygotes for the common D allele.
It has also been reported that carriers of the 68 bp
allele in the CBS gene had a mean homocysteine 0.8
nM/ml lower than those lacking the allele, and in the
group of men homozygous for the common D/D allele,
those lacking the CBS 68 bp allele had a median
homocysteine 1.0 nM/ml higher than those also carrying
the 68bp allele in a genetic interaction analysis (Dekou
et al., 2001). Taken together, these findings suggest that
there is a biological “cross-talk” between the re-
methylation and the trans-sulfuration pathway in deter-
mining plasma homocysteine levels (Dekou et al.,
2001). In subjects with MS D/D genotype, the odds ratio
for comparing the MTHFR A/A genotype with A/V or V/
V genotype increased to 1.99 in a Japanese study to
assess the association between late onset vascular
disease including ischemic stroke and the A/V poymor-
phism of MTHFR (Morita et al., 1998). A recent study
have documented the evidence of polygenic regulation
of plasma homocysteine, thus providing new insights of
the importance of genetic influences in carriers of
common polymorphic traits, which predisposed them to
either higher or lower homocysteine concentration (Tsai
et al., 2000). Therefore, our case study suggests that
the interactions of the CBS 68 bp allele with MTHFR V/
V homozygosity and with MS D/D homozygosity in
determining plasma levels of homocysteine could be
additive and of clinical importance, especially in the
thrombotic patients at young ages. However, there
appear to be no prospective data on the association of
these polygenic effects on homocysteine levels with
incidence or onset of ischemic stroke.
The limitation of this study is that we could not
measure plasma homocysteine levels in the probands
family members, which have made us impossible to
observe the cosegregation of genotypes and phenotypes
in this family. Anyway, the summary odds ratios of all the
previous studies for patients with hyperhomocysteinemia
were reported to be 2.5 for cerebrovascular disease
(Markis, 2000). Therefore, additional prospective studies
are needed to clarify these potential polygenic risk
factors and clinical significance for stroke. In conclusion,
disturbances of re-methylation enzymes (MTHFR, MS),
or deficiencies of the trans-sulfuration enzyme (CBS) as
well as role of genetic factors of these genes should be
considered in association with hyperhomocysteinemia,
particularly in thrombotic patients with no other acquired
or hereditary causes (Fodinger et al., 1999; Markis, 2000).
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